TARGACEPT, INC.
- Country
- πΊπΈUnited States
- Ownership
- Private, Subsidiary
- Employees
- -
- Market Cap
- -
- Website
- http://www.targacept.com
Clinical Trials
19
Trial Phases
2 Phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (16 trials with phase data)β’ Click on a phase to view related trials
Study Evaluating the Effect of TC-6499 on Gastric Emptying Time in Diabetic Subjects With Gastroparesis
- First Posted Date
- 2014-07-10
- Last Posted Date
- 2015-05-12
- Lead Sponsor
- Targacept Inc.
- Target Recruit Count
- 80
- Registration Number
- NCT02187094
- Locations
- πΊπΈ
Horizon Research Group, Inc., Mobile, Alabama, United States
πΊπΈPrefered Research Partners, Inc., Little Rock, Arkansas, United States
πΊπΈProfil Institute for Clinical Research, Inc., Chula Vista, California, United States
Study Evaluating the Safety, Tolerability, and Efficacy of Dexmecamylamine (TC-5214) for Treatment of Overactive Bladder
- First Posted Date
- 2013-06-04
- Last Posted Date
- 2015-06-03
- Lead Sponsor
- Targacept Inc.
- Target Recruit Count
- 1635
- Registration Number
- NCT01868516
- Locations
- πΊπΈ
Simon-Williamson Clinic, P.C., Birmingham, Alabama, United States
πΊπΈPhysician's Resource Group, Dothan, Alabama, United States
πΊπΈCoastal Clinical Research, Inc., Mobile, Alabama, United States
Efficacy, Safety, and Tolerability of TC-5619 as Augmentation Therapy to Improve Negative Symptoms and Cognition in Outpatients With Schizophrenia
- Conditions
- Cognitive DysfunctionSchizophreniaNegative Symptoms
- Interventions
- Drug: Placebo
- First Posted Date
- 2011-12-08
- Last Posted Date
- 2015-06-03
- Lead Sponsor
- Targacept Inc.
- Target Recruit Count
- 603
- Registration Number
- NCT01488929
- Locations
- πΊπΈ
Collaborative Neuroscience Network, Inc, Garden Grove, California, United States
πΊπΈBehavorial Research Specialists, Glendale, California, United States
πΊπΈApostle Clinical Trials, Inc, Long Beach, California, United States
Safety & Efficacy of TC-5619 in Adults With Inattentive-predominant Attention Deficit/Hyperactivity Disorder (ADHD)
- Conditions
- Attention Deficit Hyperactivity Disorder
- Interventions
- Drug: TC-5619-238 25mgDrug: PlaceboDrug: TC-5619-238 5mg
- First Posted Date
- 2011-11-17
- Last Posted Date
- 2013-04-30
- Lead Sponsor
- Targacept Inc.
- Target Recruit Count
- 250
- Registration Number
- NCT01472991
- Locations
- πΊπΈ
Southwestern Research, Inc, Beverly Hills, California, United States
πΊπΈSynergy Clinical Research Center, National City, California, United States
πΊπΈMCB Clinical Research Centers, LLC, Colorado Springs, Colorado, United States
Efficacy, Safety, & Tolerability of AZD3480 Patients With Mild to Moderate Dementia of the Alzheimer's Type (AD)
- First Posted Date
- 2011-11-06
- Last Posted Date
- 2015-06-03
- Lead Sponsor
- Targacept Inc.
- Target Recruit Count
- 386
- Registration Number
- NCT01466088
- Locations
- πΊπΈ
Banner Alzheimer Institute, Phoenix, Arizona, United States
πΊπΈMeridien Research, Brooksville, Florida, United States
πΊπΈMD Clinical, Hallandale Beach, Florida, United States
- Prev
- 1
- 2
- 3
- 4
- Next